Form 4: Oruka CMO Exercises Options, Sells Shares in Pre-Planned Trade

Oruka Therapeutics' Chief Medical Officer, Joana Goncalves, exercised stock options and warrants, then sold a portion of the acquired common stock under a pre-arranged trading plan.

Summary

• Joana Goncalves, Chief Medical Officer of Oruka Therapeutics, Inc. (ORKA), executed transactions on January 15, 2026.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan established on September 19, 2025.
• Goncalves acquired 3,500 shares of common stock by exercising employee stock options at $6.84 per share.
• An additional 3,500 shares of common stock were acquired by exercising employee warrants at $7.80 per share.
• A total of 6,999 shares of common stock were sold: 4,381 shares at a weighted average price of $31.5626 (ranging from $30.86 to $31.85) and 2,619 shares at a weighted average price of $32.237 (ranging from $31.86 to $32.71).
• Following these transactions, Goncalves directly owns 1,518 shares of common stock, 221,563 employee stock options, and 192,992 employee warrants.

Sentiment

Score: 5

Explanation: The filing reports a routine, pre-planned insider transaction involving the exercise of options/warrants and subsequent sale of shares. While it represents a net reduction in direct common stock ownership by a key executive, the pre-planned nature mitigates negative sentiment, making it a neutral event from a market signaling perspective.

Positives

• The Chief Medical Officer realized significant gains by selling shares at an average price over $31, substantially higher than the exercise prices of $6.84 and $7.80.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a structured approach to managing personal holdings rather than a reaction to immediate company news.

Negatives

• The Chief Medical Officer's direct beneficial ownership of common stock decreased by 6,999 shares, representing a net reduction in direct equity holdings.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing details a routine insider transaction and does not provide information directly related to broader industry trends or competitor activities.

Corporate Governance

Stakeholder Impact

• Shareholders may view the insider selling, even if pre-planned, with slight caution, though the routine nature and significant remaining derivative holdings temper any strong negative signal.

Next Steps

• Continued vesting of the remaining employee stock options and warrants held by Joana Goncalves, with 1/4 vesting on April 18, 2025, and 1/48 monthly thereafter.

Key Dates

Recommendation

The filing details a routine insider transaction where the Chief Medical Officer exercised vested options and warrants, then sold a portion of the acquired shares under a pre-arranged 10b5-1 trading plan. While it represents insider selling, the pre-planned nature reduces its signaling impact. It does not provide new fundamental information to change the investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

Oruka Therapeutics, ORKA, Form 4, Insider Trading, Stock Options, Stock Warrants, Share Sale, Chief Medical Officer, Rule 10b5-1 Plan